2021
Pan‐cancer analysis of prognostic metastatic phenotypes
Zaorsky NG, Wang X, Garrett SM, Lehrer EJ, Lin C, DeGraff DJ, Spratt DE, Trifiletti DM, Kishan AU, Showalter TN, Park HS, Yang JT, Chinchilli VM, Wang M. Pan‐cancer analysis of prognostic metastatic phenotypes. International Journal Of Cancer 2021, 150: 132-141. PMID: 34287840, PMCID: PMC8595638, DOI: 10.1002/ijc.33744.Peer-Reviewed Original ResearchConceptsLiver/lung metastasisLung metastasesOverall survivalMetastatic cancerConcordance indexCancer stage IV diseaseCox proportional hazards modelMetastatic phenotypeNational Cancer DatabaseStage IV diseaseEnd Results (SEER) databaseAmerican Joint CommitteeLong-term survivorsLatent class analysisProportional hazards modelStage IVANomogram modelResults databaseSurvival outcomesBetter prognosticationCancer DatabasePan-cancer analysisClinical trialsHazards modelJoint Committee
2016
Who benefits from chemoradiation in stage III–IVA endometrial cancer? An analysis of the National Cancer Data Base
Lester-Coll NH, Park HS, Rutter CE, Corso CD, Young MR, Ratner ES, Litkouhi B, Decker RH, Yu JB, Damast S. Who benefits from chemoradiation in stage III–IVA endometrial cancer? An analysis of the National Cancer Data Base. Gynecologic Oncology 2016, 142: 54-61. PMID: 27151429, DOI: 10.1016/j.ygyno.2016.04.544.Peer-Reviewed Original ResearchConceptsAdvanced endometrial cancerImproved overall survivalNational Cancer Data BaseOverall survivalHistologic gradeEndometrial cancerCox proportional hazards regressionPropensity scoreMultivariable subgroup analysisSignificant OS benefitGrade 1 patientsProportional hazards regressionKaplan-Meier estimatesLog-rank testLack of benefitOS benefitAdjuvant therapyStage IIIAStage IVAFIGO stageAdjuvant CRTHazards regressionTumor sizeRegional radiotherapySubgroup analysis